ArticleMolecular genetics and genomics : MGG2022

Hyperlipidemia patients carrying LDLR splicing mutation c.1187-2A>G respond favorably to rosuvastatin and PCSK9 inhibitor evolocumab.

Xiaoyu Zhang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.